Published in J Immunol on March 01, 2007
Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology (2009) 2.44
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol (2008) 1.45
Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39
Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid (2008) 1.21
Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol (2010) 1.11
Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci (2014) 1.03
Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab (2012) 1.01
Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease. World J Surg (2016) 1.00
Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci U S A (2012) 0.97
B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol (2008) 0.96
PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy. PLoS One (2010) 0.93
Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab (2014) 0.90
Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy. Clin Exp Immunol (2010) 0.85
The thymus and the immune system: layered levels of control. J Thorac Oncol (2010) 0.81
Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17. PLoS One (2012) 0.81
Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes (2008) 0.81
Improvement of thyroid eye disease following treatment with the cyclooxygenase-2 selective inhibitor celecoxib. Thyroid (2008) 0.79
Graves orbitopathy: a perspective. Nat Rev Endocrinol (2009) 0.77
Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naïve rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment. Rheumatol Int (2011) 0.77
Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmol (2016) 0.76
Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves' disease: evidence for a phenotypic signature ascribable to nongenetic factors. J Clin Endocrinol Metab (2009) 0.76
Space radiation exposure persistently increased leptin and IGF1 in serum and activated leptin-IGF1 signaling axis in mouse intestine. Sci Rep (2016) 0.75
Histopathologic analysis of palpebral conjunctiva in thyroid-related orbitopathy (an american ophthalmological society thesis). Trans Am Ophthalmol Soc (2010) 0.75
Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells. J Clin Endocrinol Metab (2014) 0.75
Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. Expert Rev Ophthalmol (2014) 0.75
Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface. Clin Diabetes Endocrinol (2016) 0.75
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology (2009) 2.44
Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev (2003) 2.23
Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2009) 2.10
Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol (2003) 1.75
Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol (2003) 1.51
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol (2008) 1.45
Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol (2002) 1.36
Improved detection of DNA motifs using a self-organized clustering of familial binding profiles. Bioinformatics (2005) 1.29
Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol (2002) 1.26
Pancreatic neuroendocrine tumors. Endocr Res (2011) 1.26
Isolation and phenotypic characterization of lung fibroblasts. Methods Mol Med (2005) 1.24
Integrated microfluidic tmRNA purification and real-time NASBA device for molecular diagnostics. Lab Chip (2008) 1.22
More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest (2006) 1.21
Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid (2008) 1.21
IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol (2005) 1.18
Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol (2002) 1.14
Transcription factor binding site identification using the self-organizing map. Bioinformatics (2005) 1.11
Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol (2010) 1.11
Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci (2008) 1.10
Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab (2012) 1.08
Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design. Proc Natl Acad Sci U S A (2013) 1.07
Immune mechanisms in thyroid eye disease. Thyroid (2008) 1.05
Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab (2011) 1.05
Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf) (2011) 1.04
Inhibitory effect of leptin on human uterine contractility in vitro. Am J Obstet Gynecol (2006) 1.04
Modulation of human uterine smooth muscle cell collagen contractility by thrombin, Y-27632, TNF alpha and indomethacin. Reprod Biol Endocrinol (2009) 1.03
Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci (2014) 1.03
Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid (2008) 0.99
Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci U S A (2012) 0.97
Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol (2004) 0.96
B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol (2008) 0.96
Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem (2006) 0.95
Treating the thyroid in the presence of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab (2012) 0.94
Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB. Invest Ophthalmol Vis Sci (2012) 0.94
Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am J Physiol Cell Physiol (2003) 0.94
PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy. PLoS One (2010) 0.93
Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol (2011) 0.93
Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions. PLoS One (2013) 0.92
Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease. J Biol Chem (2011) 0.91
Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab (2014) 0.90
Evaluation of human endothelial cells post stent deployment in a cardiovascular simulator in vitro. Ann Biomed Eng (2009) 0.90
Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology (2006) 0.88
Rosiglitazone-induced proptosis. Arch Ophthalmol (2005) 0.88
Analysis of Maxi-K alpha subunit splice variants in human myometrium. Reprod Biol Endocrinol (2004) 0.88
Rho A/Rho kinase mRNA and protein levels in human myometrium during pregnancy and labor. J Soc Gynecol Investig (2005) 0.87
Long-term exposure of CdTe quantum dots on PC12 cellular activity and the determination of optimum non-toxic concentrations for biological use. J Nanobiotechnology (2010) 0.87
Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor. Biol Reprod (2007) 0.87
Molecular cloning of an IL-8-like CXC chemokine and tissue factor in rainbow trout (Oncorhynchus mykiss) by use of suppression subtractive hybridization. Cytokine (2002) 0.86
Functional coupling of beta3-adrenoceptors and large conductance calcium-activated potassium channels in human uterine myocytes. J Clin Endocrinol Metab (2005) 0.86
Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. J Immunol (2005) 0.86
Uterine contractility of plants used to facilitate childbirth in Nigerian ethnomedicine. J Ethnopharmacol (2012) 0.86
Human chorionic gonadotrophin relaxation of human pregnant myometrium and activation of the BKCa channel. J Clin Endocrinol Metab (2003) 0.86
Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. Thyroid (2008) 0.85
Divergent expression of IL-1 receptor antagonists in CD34⁺ fibrocytes and orbital fibroblasts in thyroid-associated ophthalmopathy: contribution of fibrocytes to orbital inflammation. J Clin Endocrinol Metab (2013) 0.85
Acute phase gene expression in rainbow trout (Oncorhynchus mykiss) after exposure to a confinement stressor: A comparison of pooled and individual data. Fish Shellfish Immunol (2009) 0.85
Testes and brain gene expression in precocious male and adult maturing Atlantic salmon (Salmo salar). BMC Genomics (2010) 0.85
Expression of thyrotropin receptor, thyroglobulin, sodium-iodide symporter, and thyroperoxidase by fibrocytes depends on AIRE. J Clin Endocrinol Metab (2014) 0.84
Upregulation of PSCDBP, TLR2, TWIST1, FLJ35382, EDNRB, and RGS12 gene expression in human myometrium at labor. Reprod Sci (2008) 0.84
Characterization of the anaemia associated with Graves' disease. Clin Endocrinol (Oxf) (2008) 0.84
Differential expression of the metalloproteinase MMP3 and the alpha5 integrin subunit in human myometrium at labour. Mol Hum Reprod (2007) 0.83
Pharmacotherapy: does selenium supplementation improve Graves ophthalmopathy? Nat Rev Endocrinol (2011) 0.83
Isolation and characterization of the bovine Stearoyl-CoAdesaturase promoter and analysis of polymorphisms in the promoter region in dairy cows. Mamm Genome (2005) 0.83
tmRNA--a novel high-copy-number RNA diagnostic target--its application for Staphylococcus aureus detection using real-time NASBA. FEMS Microbiol Lett (2009) 0.83
Is IGF-I receptor a target for autoantibody generation in Graves' disease? J Clin Endocrinol Metab (2013) 0.82
Gene prediction using the Self-Organizing Map: automatic generation of multiple gene models. BMC Bioinformatics (2004) 0.82
B cell depletion in Graves' disease: the right answer to the wrong question? J Clin Endocrinol Metab (2007) 0.82
Expression of RHOGTPase regulators in human myometrium. Reprod Biol Endocrinol (2008) 0.82
Cloning and characterization of two genes encoding rainbow trout homologues of the IFITM protein family. Vet Immunol Immunopathol (2006) 0.82
Rapid detection of Listeria monocytogenes in food using culture enrichment combined with real-time PCR. Food Microbiol (2008) 0.82
Human fibrocytes express multiple antigens associated with autoimmune endocrine diseases. J Clin Endocrinol Metab (2014) 0.81
Ritonavir-associated hyperparathyroidism, osteopenia and bone pain. AIDS (2002) 0.81
Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17. PLoS One (2012) 0.81
Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts. Endocrinology (2006) 0.81
Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes (2008) 0.81
Self-organizing neural networks to support the discovery of DNA-binding motifs. Neural Netw (2006) 0.81
Regulation of IL-1 receptor antagonist by TSH in fibrocytes and orbital fibroblasts. J Clin Endocrinol Metab (2014) 0.80
Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid (2011) 0.80
Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Arch Ophthalmol (2009) 0.79
Molecular cloning and expression analysis of rainbow trout (Oncorhynchus mykiss) matrix metalloproteinase-9. Fish Shellfish Immunol (2004) 0.79
PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN. J Clin Endocrinol Metab (2014) 0.79
Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases. Annu Rev Pharmacol Toxicol (2012) 0.79
Cytokine-induced lymphocyte chemoattraction from cultured human thyrocytes: evidence for interleukin-16 and regulated upon activation, normal T cell expressed, and secreted expression. Endocrinology (2003) 0.79
Ghrelin in the human myometrium. Reprod Biol Endocrinol (2010) 0.79
Thyroid eye disease: towards an evidence base for treatment in the 21st century. Curr Neurol Neurosci Rep (2012) 0.78
The relaxant effect of nifedipine in human uterine smooth muscle and the BK(Ca) channel. Am J Obstet Gynecol (2008) 0.78
Molecular pathology of Muller's muscle in Graves' ophthalmopathy. J Clin Endocrinol Metab (2005) 0.78
A novel ELISpot method for adherent cells. J Immunol Methods (2004) 0.78
Expression levels of mRNA for Rho A/Rho kinase and its role in isoprostane-induced vasoconstriction of human placental and maternal vessels. Reprod Sci (2007) 0.77
Cytoplasmic prostaglandin E2 synthase is dominantly expressed in cultured KAT-50 thyrocytes, cells that express constitutive prostaglandin-endoperoxide H synthase-2. Basis for low protaglandin E2 production. J Biol Chem (2002) 0.77